Skip to Main Content
SickKids
How research infrastructure is being mobilized to advance Precision Child Health
7 minute read

How research infrastructure is being mobilized to advance Precision Child Health

Summary:

From PCHSeq and whole-genome sequencing to precision oncology and complex health data tailored around each unique child, SickKids research is generating new insights to support more individualized approaches to diagnosis, treatment and prevention.

Two researchers work with a pipette and other laboratory equipment at a SickKids research lab.

This story originally appeared in an Excellence in Research and Innovation sponsored feature in The Globe and Mail. Read the original story.

The Hospital for Sick Children (SickKids) in Toronto is widely recognized as Canada’s pre-eminent research institution, with a world-class ecosystem for discovery, innovation and clinical care. Empowered by a combination of world-leading experts, state-of-the art technologies and collaborative networks, SickKids has spearheaded important breakthroughs in genomics, cancer and many other areas of pediatric medicine.

More advances are on the horizon as SickKids pursues its mission to realize the promise of “precision child health” – individualized care for every child based on understanding and analysis of the full range of factors determining their health status, including genetic, biological, environmental and social. This movement away from one-size-fits-all medicine is a path towards faster diagnosis, more effective treatments, and better risk prediction and prevention of serious health outcomes.

Achieving the vision depends on bringing research and care more closely together, supported by the research infrastructure and expertise needed to generate, connect and analyze complex health information at scale.

Advances in genomics have transformed many aspects of diagnosis and treatment at SickKids, and the power to unlock the genetic code of patients has fuelled much of the drive towards precision child health.

“There are at least 6,000 rare genetic diseases or disorders, and 50 per cent of the pediatric patients hospitalized at SickKids have one of these conditions,” says Stephen Scherer, chief of research at SickKids.

“The needs of our patients and their families have led us to significantly invest in strengthening our genetic capabilities over the years, and today we are using cutting-edge technologies, including whole-genome sequencing, to diagnose and treat genetic disorders more quickly and precisely.”

SickKids is taking another step forward through a project funded by Genome Canada, Precision Child Health – Comprehensive Sequencing for Childhood Life-long Disorders (PCHSeq). Over four years, PCHSeq will sequence the complete genome of 10,000 participants through The Centre for Applied Genomics (TCAG), SickKids’ genomics research facility and a node of CGEn, Canada’s national platform for genome sequencing and analysis.

PCHSeq is part of a larger Canadian Precision Health Initiative, a national effort to build a genomic data resource of more than 100,000 human genomes reflecting Canada’s diverse population, with much of the sequencing happening at TCAG.

Through PCHSeq, SickKids will create a large dataset reflecting diverse participants spanning different childhood-onset disorders, including family members. The goal is to expand access to whole-genome sequencing for children who may benefit from genetic testing.

Before genetic breakthroughs, many families faced “diagnostic odysseys,” seeing their child go through test after test, and too often, ending up with no answers.

“Then we had the capacity to test one gene at a time, based on the hypothesis that ‘gene X’ is known to be involved in these specific clinical symptoms, so let’s check it first and then go down the line,” Dr. Scherer explains.

Sequential single-gene testing is costly and time-consuming, he says. “Decoding all of a person’s DNA increases the likelihood that we’ll quickly find the contributing change, as well as other gene alterations that can be treated as well.”

The PCHSeq project will extend research genome sequencing into areas where it has not historically been available. Among the disease areas to be included are cardiovascular disease, cancer, immune conditions and gastrointestinal disorders, as well as rare diseases and broader genetic conditions such as cystic fibrosis, muscular dystrophy and epilepsy. The project will build on SickKids’ work in “precision oncology,” where great strides have been made in the diagnosis and treatment of childhood cancers, as well as in identifying specific cancer risks.

In cancer, alterations in DNA disrupt normal molecular processes, causing cells to uncontrollably grow and divide. Research into the molecular changes occurring in tumours has given clinicians important new capabilities, says David Malkin, co-director of SickKids’ Cancer Genetics Program, a senior staff oncologist and co-lead of Precision Child Health.

“Looking at the molecular architecture of the cancer allows for a more precise diagnosis and can guide us in the use of drugs specifically designed to target those changes,” Dr. Malkin says. “This differs from conventional chemotherapy and radiation treatment, which often affect normal cells as well and cause lifelong side effects.”

Advances in understanding tumours and predicting how they will respond to different therapies are not only changing the future but are already making a difference, he says. “We apply all this new knowledge directly into patient care. We are seeing earlier detection of tumours and watching survival rates improve. While this is valuable science that will give us new treatments 10 to 15 years down the road, it is also being integrated into clinical care to benefit the patients we see today.”

Precision oncology also enhances the ability to predict cancers that might develop down the road. Dr. Malkin’s own research explores an uncommon cancer predisposition disorder called Li-Fraumeni syndrome, which led to a protocol used around the world to detect tumours early and improve survival in affected families.

Precision child health is also transforming understanding and treatment of respiratory disorders and diseases such as asthma, a research specialty of Dr. Padmaja Subbarao, associate chief of clinical research, staff respirologist and co-lead of Precision Child Health with Dr. Malkin.

“Asthma is a complex multi-genetic disorder, but beyond the genetic causes, the risks and outcomes depend very much on environmental factors – how genetic predispositions interact with air quality, exposure to respiratory irritants and more,” Dr. Subbarao says. “A child’s profile also needs to include their socioeconomic context, as that also has health impacts.”

Dr. Subbarao is leading research uncovering new insights to prevent, predict and treat asthma, allergies and other childhood diseases, based on the interaction of genetic, environmental, lifestyle and early-life microbial factors (including the infant gut microbiome).

The CHILD Cohort Study is a nationwide, multi-centre study that tracked 3,500 Canadian children from birth to age 16. Findings included links between low lung function from birth and early viral infections and asthma, as well as how air pollution exposures were associated with poorer lung growth and greater allergic sensitization. Some SickKids CHILD participants will have their genomes sequenced via PCHSeq.

“Artificial intelligence and increased computing capacity make it more feasible to analyze all relevant factors to more precisely predict an individual’s health trajectory and plan the best therapies,” says Dr. Subbarao.

A recent large equipment grant from CFI, including for new machine learning platforms and AI-powered tools, will strengthen SickKids’ capacity to generate, integrate and analyze complex health data to support research and clinical application.

The development of this powerful knowledge source relies on partnership between SickKids’ researchers and clinicians and patients and their families, says Dr. Subbarao.

“This is a shared journey. We can only advise depending on the information that patients are willing to share, and one of our goals is to increase patients’ trust in science and research.”

Part of that trust is built through clear processes for giving consent to have patient data captured and analyzed, as well as to broaden access to clinical trials.

“Clinical trials are key pathways to creating human impact and changing the way we care for patients. We are looking at how to make trials more generalizable and easier for patients to access,” she says.

Strengthening clinical trials and the advances generated by the PCHSeq project will enable the building of knowledge to make precision child health a reality, improving the health of patients of today as well as those of future generations.

Precision Child Health is a SickKids movement to individualize care by understanding each unique child, bringing research and care together to diagnose faster, treat smarter and predict better.
Learn about Precision Child Health
Back to Top